RAUL CORTES LADINO: Open Payments
NPI 1558510511 · MIAMI BEACH, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$271 in 13 payments from 10 companies in 2025. Trend: 2023 $1,996 · 2024 $4,024 · 2025 $271
Food & beverage: $271
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 2 | $51 |
| Astellas Pharma US Inc | 2 | $43 |
| Eisai Inc. | 2 | $42 |
| TerSera Therapeutics LLC | 1 | $34 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| Incyte Corporation | 1 | $20 |
| BeOne Medicines USA, Inc. | 1 | $16 |
| TOLMAR, INC. | 1 | $14 |
| pharmaand GmbH | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
Products named: Enhertu, Xospata, Lenvima, Zoladex, RUBRACA, WELIREG, JAKAFI, TEVIMBRA.
Industry payments across FL — which companies pay providers there.
